| Prev Close | 16.36 |
| Open | 16.39 |
| Day Low/High | 16.20 / 16.85 |
| 52 Wk Low/High | 2.35 / 23.34 |
| Volume | 5.37M |
| Avg Volume | 10.11M |
Amarin Corp. Plc (AMRN)
16.61
0.25
1.53
NASDAQ : Health Technology
| Exchange | NASDAQ |
| Shares Outstanding | 293.58M |
| Market Cap | 5.21B |
| EPS | -0.20 |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Latest News
There Are No Safe Havens Right Now
The indices need to find support and we need some better pockets of strength.
Play Amarin's 'Home-Run Potential'
Latest trial results appear to show the biotech has a super fish oil pill with potential to aid those with high triglycerides.
Amarin Continues to Impress
The market continues to be flat as we enter the last hour of the trading week. It looks like the SCOTUS nomination fight will drag out for at least another divisive week as a couple of Republican senators cave in supporting another FBI investigatio...
Facebook Battles Negative Sentiment and a Weak Chart
The market is in no mood to give the benefit of the doubt to a stock acting as poorly as Facebook.
Another Day of Rotation, but of a Different Sort
Big-cap FAANG names and Apple, in particular, were the beneficiaries.
Amarin's Huge Rally: Here's Why the Stock Is Soaring and How to Trade It
For equity holders in Amarin, now's the time to be implementing my 'Jensen Rules.'
Sirius XM May Have Opened Pandora's Box With Takeover Announcement
The satellite radio operator's stock is declining after announcing the purchase of the streaming radio service.
Stocks Wake Up After Hard Selloff
Stock buyers are back after Thursdays selloff helped by Pandora's jump higher. Dell's disaster continues and China has a fat finger trade.
Amarin Stock May Be Worth the Wait
A growing and aging population ensures biotechs won't go out of style.
Futures Rise on Key Earnings
US stock futures are rising on strong earnings from DuPont and Coach, while Amarin gets a nod from the FDA - Debra Borchardt gives details.
The Next Big Thing in Biotech: J.P. Morgan Conference
Adam Feuerstein, senior columnist for TheStreet, says the coming week's J.P. Morgan Healthcare Conference is the next big thing in biotech.
The Next Big Thing in Biotech
Adam Feuerstein, senior columnist for TheStreet, says biotech earnings are the next big thing to watch in biotech.
Catch a Ride if You Can
Be willing to chase this rally, even though it's disliked by so many market players.
The Next Big Thing in Biotech: FDA Approvals
Senior columnist Adam Feuerstein says post-FDA approval trading is the next big thing to watch in biotech.
The Next Big Thing in Biotech: Amarin, Onyx
Adam Feuerstein, senior columnist for TheStreet, says Amarin and Onyx are the next big things in biotech.
3 Stocks I Saw on TV, July 12
Dan Fitzpatrick examines three stocks viewed on Fast Money. Today's stocks include Tibco Software, Arena Pharma, and Church & Dwight.
AZO Could be the Next Shoe to Drop
After AAP and ORLY warn, one has to be very cautious with Autozone.
Trust Level Is Low
The downtrend isn't over yet, so you might as well knock out some trades in the short term.
Uncertainty Reigns
I have little trust, so I'm sticking with small, quick day-trades.
Risk Is High
But you can deal with it by playing fast and tight.
Renting, Not Buying
I'm playing the bounce and taking on a few trades.
May, or May Not, Day
Market strength on May 1 is not necessarily an indication that a rally will follow.
Playing Tight
If the market retests early lows, all bets are off.